News

The acquisition will include blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). According to the agreement, Micromet’s Munich

The wholly owned subsidiary will provide pharmaceutical sales teams with operational and human resources (HR) support. The new business unit will expand Mission’s Northeastern US presence which also

Technoclone is a reagent specialist in thrombosis and cardiovascular diagnostics. The collaboration is believed to support Roche’s plans to develop a new line of analyzers for the central

Alferon N Injection (Interferon alfa-n3 (human leukocyte derived)) is even approved in the US for the treatment of refractory or recurring external condylomata acuminate (genital warts) in adults.

The FDA has announced that Formatech, was not in compliance with its current Good Manufacturing Practice (cGMP) requirements during the period that the iSONEP clinical vials were filled.

The European approval enables Charter Medical to begin marketing and selling the newly designed and expanded product offering for cryogenic storage, preservation, and transfer of HPCs in Europe.

As per the settlement agreement, Mallinckrodt has granted Watson a royalty-free license to US patents relating to Exalgo. Watson will have the right to launch its bioequivalent products

Case studies were also presented on two patients with relapsed peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) who were treated with ADCETRIS. ADCETRIS is an antibody-drug conjugate (ADC) directed

Under the deal, CPR+ customers will have access to Armada’s value-added services within CPR+ and will be able to integrate those services within their workflow in the pharmacy